Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to give psoriasis patients their life back

NCT ID NCT05701995

Symptom relief Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the drug deucravacitinib can improve quality of life for adults with moderate-to-severe plaque psoriasis. 180 participants received either the drug or a placebo. The main goal was to see if more people on the drug reported no or minimal impact of their skin condition on daily life after 16 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

180 people

The number who actually took part.

Started

Jan 2023

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Men and women diagnosed with stable plaque psoriasis for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator. * Deemed by the investigator to be a candidate for phototherapy or systemic therapy. * ≥ 3% of Body Surface Area (BSA) involvement at the Screening Visit and Day 1 * Dermatology Life Quality Index (DLQI) score \> 5 at the Screening Visit and Day 1 * Moderate-to-severe plaque psoriasis as defined by static Physician Global Assessment (s-PGA) ≥ 3 at the Screening Visit and Day 1 Exclusion Criteria: Target Disease Exceptions: * Non-plaque psoriasis (that is, guttate, pustular, erythrodermic, palmoplantar only involvement or drug-induced psoriasis) at Screening Visit or Day 1 Other protocol-defined inclusion/exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis

Contacts and locations

Locations

  • Local Institution - 0001

    Rochester, New York, 14623, United States

  • Local Institution - 0002

    Waterford, Michigan, 48328, United States

  • Local Institution - 0003

    Baton Rouge, Louisiana, 70809, United States

  • Local Institution - 0004

    Bakersfield, California, 93309, United States

  • Local Institution - 0005

    Bexley, Ohio, 43209, United States

  • Local Institution - 0006

    Phoenix, Arizona, 85006, United States

  • Local Institution - 0007

    Rolling Meadows, Illinois, 60008, United States

  • Local Institution - 0008

    South Jordan, Utah, 84095, United States

  • Local Institution - 0009

    Sacramento, California, 95815, United States

  • Local Institution - 0010

    Auburn Hills, Michigan, 48326, United States

  • Local Institution - 0012

    Mayfield Heights, Ohio, 44124, United States

  • Local Institution - 0013

    New York, New York, 10128, United States

  • Local Institution - 0014

    Spokane, Washington, 99202, United States

  • Local Institution - 0015

    North Little Rock, Arkansas, 72117, United States

  • Local Institution - 0016

    Coral Gables, Florida, 33134, United States

  • Local Institution - 0017

    Las Vegas, Nevada, 89148, United States

  • Local Institution - 0018

    Rockville, Maryland, 20850, United States

  • Local Institution - 0019

    Charleston, South Carolina, 29407, United States

  • Local Institution - 0020

    Snellville, Georgia, 30078, United States

  • Local Institution - 0021

    Bellevue, Washington, 98004, United States

  • Local Institution - 0022

    San Diego, California, 92103, United States

  • Local Institution - 0024

    Washington D.C., District of Columbia, 20016, United States

  • Local Institution - 0025

    Skokie, Illinois, 60077, United States

  • Local Institution - 0027

    Brandon, Florida, 33511, United States

  • Local Institution - 0028

    Frisco, Texas, 75034, United States

  • Local Institution - 0029

    Cypress, Texas, 77433, United States

  • Local Institution - 0030

    Centennial, Colorado, 80111, United States

  • Local Institution - 0031

    Mill Creek, Washington, 98012, United States

  • Local Institution - 0032

    New York, New York, 10011, United States

  • Local Institution - 0033

    Springville, Utah, 84663, United States

  • Local Institution - 0034

    Scottsdale, Arizona, 85260, United States

  • Local Institution - 0035

    Reno, Nevada, 89509, United States

  • Local Institution - 0036

    Springfield, Illinois, 62703, United States

  • Local Institution - 0037

    Atlanta, Georgia, 30331, United States

  • Local Institution - 0038

    Carolina, 00985, Puerto Rico

  • Local Institution - 0039

    San Juan, 00917, Puerto Rico

  • Local Institution - 0040

    Caguas, 00727, Puerto Rico

  • Riverchase Dermatology

    Pembroke Pines, Florida, 33028, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.